A discounted “picks-and-shovels” cannabinoid API platform—levered to global medical growth and U.S. Schedule III research, but still proving the turnaround.
Overview
MediPharm Labs is a specialized, pharmaceutical-grade cannabinoid manufacturer that has evolved from a Canada-centric extractor (founded 2015) into a more diversified global platform focused on regulated medical markets and pharma/B2B supply. The company now runs four revenue pillars—International Medical, Canadian Medical, Pharmaceutical/B2B (APIs and clinical materials), and Canadian Adult-Use/Wellness—explicitly using this mix to reduce exposure to the volatile, price-compressed Canadian recreational channel. Its product set spans high-purity oils and tinctures, softgels, gummies/soft chews, minor-cannabinoid formulations, and precision delivery systems such as metered-dose inhalers. The strategic pivot is showing up in results: in 2025, international medical revenue rose ~43% YoY to become >50% of total revenue. MediPharm’s core differentiation is regulatory readiness (EU GMP, TGA, ANVISA, Health Canada DEL), positioning it to win higher-margin medical and clinical-trial business globally and potentially benefit from U.S. Schedule III rescheduling-driven research demand.